𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Axial myopathy in parkinsonism

✍ Scribed by Julia V. Wanschitz; Martin Sawires; Klaus Seppi; Sylvia Boesch; Wolfgang N Loescher; Michael Schocke; Werner Poewe


Book ID
102506387
Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
256 KB
Volume
26
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Myopathy and parkinsonism in phosphoglyc
✍ Evangelia Sotiriou; Paul Greene; Sindu Krishna; Michio Hirano; Salvatore DiMauro πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 208 KB

## Abstract A 25‐year‐old man with exertional myoglobinuria had no evidence of hemolytic anemia, but he had severe parkinsonism that was responsive to levodopa. Phosphoglycerate kinase (PGK) activity was markedly decreased in muscle, and molecular analysis of the __PGK1__ gene identified the p.T378

Atypical Parkinsonism in distal myopathy
✍ Tomohiko Ishihara; Tetsutaro Ozawa; Shuichi Igarashi; Yuko Kitsukawa; Masahito T πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 244 KB

## Abstract A patient with distal myopathy with rimmed vacuoles (DMRV) exhibited Parkinsonism with a severe writing tremor that responded poorly to levodopa. Molecular genetic analysis revealed that the patient had the D176V/V572L compound heterozygous mutation in the UDP‐__N__‐acetylglucosamine 2‐

Axial myopathy – an unrecognised entity
✍ I. Mahjneh; G. Marconi; A. Paetau; A. Saarinen; T. Salmi; H. Somer πŸ“‚ Article πŸ“… 2002 πŸ› Springer 🌐 English βš– 835 KB
Axial myopathy due to primary amyloidosi
✍ Yael Friedman; John T. Paul; Jean Turley; Lili-Naz Hazrati; David Munoz πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 256 KB
Botulinum toxin treatment of lateral axi
✍ Laura Bonanni; Astrid Thomas; Sara Varanese; Vincenzo Scorrano; Marco Onofrj πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 130 KB

## Abstract Lateral axial dystonia (LAD) has been described in patients with Parkinson's disease (PD), but treatment might be more controversial than treatment of LAD in other neurological conditions. Our study was designed as a blinded cross‐over with botulinum toxin (BTX) and placebo in order to